Misplaced Pages

Insulin icodec/semaglutide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Combination drug Pharmaceutical compound

Insulin icodec/semaglutide
Combination of
Insulin icodec	Insulin analog
Semaglutide	GLP-1 receptor agonist
Clinical data
ATC code	None

Insulin icodec/semaglutide is an experimental fixed-dose combination of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk.

References

Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN 1869-6953. PMC 8342688. PMID 34268675.
"CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.
"Novo Nordisk's Insulin Products, Pipeline May Energize The Stock (NYSE:NVO) | Seeking Alpha". seekingalpha.com. 12 February 2020. Retrieved 5 November 2023.